PerkinElmer (NYSE:PKI) said today that it anticipates sales growth of approximately 12% for the second quarter, fueled by demand for COVID-19 tests and related products.

The Waltham, Mass.-based diagnostic and scientific instrument company said demand for its RT-PCR and serology tests, RNA extraction systems and kits and automated liquid handling instrumentation was particularly robust. COVID-19 related solutions contributed approximately $190 million of revenue in the quarter ended July 5, 2020, the company noted.

Get the full story on our sister site, Drug Discovery & Development.